Comparative analysis of efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis in tertiary care hospital

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231010059674N1

Enrollment

Registered

2024-12-12

Start date

2024-05-01

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis. Psoriasis, unspecified

Interventions

Intervention 1: Control group:oral route is considered gold standard treatment in severe psoriasis so it will be considered as control group. Patients will receive 10-25 mg /week oral Methotrexate for

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients having severe psoriasis with PGA score 4 will be included in the study. Patients on biologics for last 1 year

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Patients with any major respiratory, cardiac, GI, hepatic, or renal illness Patients on biologics within last 1 year Unwilling for monthly follow-up.

Design outcomes

Primary

Measure	Time frame
PGA score. Timepoint: 4 weeks. Method of measurement: PGA score,heamoglobin level, serum ALT,serum AST, urea, Creatinine.	—

Secondary

Measure	Time frame
Relapse. Timepoint: 16 weeks. Method of measurement: PGA score.	—

Countries

Pakistan

Contacts

Public ContactMehwish Amin

National University of Medical Sciences

mehwishlaeeq8@gmail.com+92 51 9273480

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026